Read More Healthcare Industry News Thermo Fisher (NYSE: TMO) to offload Remel and Oxoid microbiology arm in $1bn Astorg deal Thermo Fisher is selling a 95% recurring revenue microbiology business near its trading lows. The real question is what Marc Casper plans to do with the cash. byVenkateshApril 28, 2026